vs
Protalix BioTherapeutics, Inc.（PLX）与TRANSACT TECHNOLOGIES INC（TACT）财务数据对比。点击上方公司名可切换其他公司
TRANSACT TECHNOLOGIES INC的季度营收约是Protalix BioTherapeutics, Inc.的1.3倍（$11.5M vs $9.1M），TRANSACT TECHNOLOGIES INC同比增速更快（11.9% vs -49.9%），Protalix BioTherapeutics, Inc.自由现金流更多（$1.6M vs $589.0K），过去两年TRANSACT TECHNOLOGIES INC的营收复合增速更高（3.5% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
该公司相关归属主体罗珀技术公司是一家控股集团，主要投资控股科技领域的各类企业，业务覆盖多个科技细分赛道，依托旗下子公司开展多元化科技业务布局。
PLX vs TACT — 直观对比
营收规模更大
TACT
是对方的1.3倍
$9.1M
营收增速更快
TACT
高出61.9%
-49.9%
自由现金流更多
PLX
多$1.0M
$589.0K
两年增速更快
TACT
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $11.5M |
| 净利润 | $-5.5M | — |
| 毛利率 | 49.4% | 47.6% |
| 营业利润率 | -51.1% | -10.1% |
| 净利率 | -60.3% | — |
| 营收同比 | -49.9% | 11.9% |
| 净利润同比 | -184.8% | — |
| 每股收益（稀释后） | $-0.06 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXTACT
| Q4 25 | $9.1M | $11.5M | ||
| Q3 25 | $17.9M | $13.2M | ||
| Q2 25 | $15.7M | $13.8M | ||
| Q1 25 | $10.1M | $13.1M | ||
| Q4 24 | $18.2M | $10.2M | ||
| Q3 24 | $18.0M | $10.9M | ||
| Q2 24 | $13.5M | $11.6M | ||
| Q1 24 | — | $10.7M |
净利润PLXTACT
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $15.0K | ||
| Q2 25 | $164.0K | $-143.0K | ||
| Q1 25 | $-3.6M | $19.0K | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | $-551.0K | ||
| Q2 24 | $-2.2M | $-319.0K | ||
| Q1 24 | — | $-1.0M |
毛利率PLXTACT
| Q4 25 | 49.4% | 47.6% | ||
| Q3 25 | 53.4% | 49.8% | ||
| Q2 25 | 62.5% | 48.2% | ||
| Q1 25 | 19.1% | 48.7% | ||
| Q4 24 | 78.7% | 44.2% | ||
| Q3 24 | 53.4% | 48.1% | ||
| Q2 24 | 29.8% | 52.7% | ||
| Q1 24 | — | 52.6% |
营业利润率PLXTACT
| Q4 25 | -51.1% | -10.1% | ||
| Q3 25 | 11.9% | 0.1% | ||
| Q2 25 | 7.5% | -1.9% | ||
| Q1 25 | -41.0% | -0.1% | ||
| Q4 24 | 39.6% | -10.3% | ||
| Q3 24 | 22.2% | -7.7% | ||
| Q2 24 | -18.0% | -3.8% | ||
| Q1 24 | — | -12.2% |
净利率PLXTACT
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | 0.1% | ||
| Q2 25 | 1.0% | -1.0% | ||
| Q1 25 | -35.8% | 0.1% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | -5.1% | ||
| Q2 24 | -16.4% | -2.8% | ||
| Q1 24 | — | -9.7% |
每股收益（稀释后）PLXTACT
| Q4 25 | $-0.06 | $-0.11 | ||
| Q3 25 | $0.03 | $0.00 | ||
| Q2 25 | $0.00 | $-0.01 | ||
| Q1 25 | $-0.05 | $0.00 | ||
| Q4 24 | $0.10 | $-0.80 | ||
| Q3 24 | $0.03 | $-0.06 | ||
| Q2 24 | $-0.03 | $-0.03 | ||
| Q1 24 | — | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $20.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $31.1M |
| 总资产 | $82.3M | $44.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXTACT
| Q4 25 | $14.7M | $20.4M | ||
| Q3 25 | $13.6M | $20.0M | ||
| Q2 25 | $17.9M | $17.7M | ||
| Q1 25 | $19.5M | $14.2M | ||
| Q4 24 | $19.8M | $14.4M | ||
| Q3 24 | $27.4M | $11.3M | ||
| Q2 24 | $23.4M | $11.1M | ||
| Q1 24 | — | $10.6M |
股东权益PLXTACT
| Q4 25 | $48.2M | $31.1M | ||
| Q3 25 | $52.9M | $31.8M | ||
| Q2 25 | $49.9M | $31.3M | ||
| Q1 25 | $45.2M | $30.9M | ||
| Q4 24 | $43.2M | $30.6M | ||
| Q3 24 | $32.4M | $38.4M | ||
| Q2 24 | $28.6M | $38.5M | ||
| Q1 24 | — | $38.6M |
总资产PLXTACT
| Q4 25 | $82.3M | $44.8M | ||
| Q3 25 | $82.3M | $45.0M | ||
| Q2 25 | $78.5M | $44.5M | ||
| Q1 25 | $73.9M | $44.2M | ||
| Q4 24 | $73.4M | $44.0M | ||
| Q3 24 | $61.6M | $50.5M | ||
| Q2 24 | $91.5M | $50.4M | ||
| Q1 24 | — | $51.9M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $609.0K |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $589.0K |
| 自由现金流率自由现金流/营收 | 17.8% | 5.1% |
| 资本支出强度资本支出/营收 | 4.4% | 0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $7.6M |
8季度趋势，按日历期对齐
经营现金流PLXTACT
| Q4 25 | $2.0M | $609.0K | ||
| Q3 25 | $-3.7M | $3.6M | ||
| Q2 25 | $-5.2M | $3.6M | ||
| Q1 25 | $-5.1M | $-161.0K | ||
| Q4 24 | $4.0M | $2.4M | ||
| Q3 24 | $4.1M | $327.0K | ||
| Q2 24 | $-3.6M | $636.0K | ||
| Q1 24 | — | $-1.5M |
自由现金流PLXTACT
| Q4 25 | $1.6M | $589.0K | ||
| Q3 25 | $-4.2M | $3.6M | ||
| Q2 25 | $-5.7M | $3.6M | ||
| Q1 25 | $-5.4M | $-171.0K | ||
| Q4 24 | $3.6M | $2.4M | ||
| Q3 24 | $4.0M | $259.0K | ||
| Q2 24 | $-3.8M | $499.0K | ||
| Q1 24 | — | $-1.6M |
自由现金流率PLXTACT
| Q4 25 | 17.8% | 5.1% | ||
| Q3 25 | -23.7% | 27.1% | ||
| Q2 25 | -36.2% | 25.9% | ||
| Q1 25 | -53.0% | -1.3% | ||
| Q4 24 | 19.6% | 23.2% | ||
| Q3 24 | 22.4% | 2.4% | ||
| Q2 24 | -28.1% | 4.3% | ||
| Q1 24 | — | -14.9% |
资本支出强度PLXTACT
| Q4 25 | 4.4% | 0.2% | ||
| Q3 25 | 2.8% | 0.5% | ||
| Q2 25 | 2.8% | 0.1% | ||
| Q1 25 | 3.0% | 0.1% | ||
| Q4 24 | 2.3% | 0.1% | ||
| Q3 24 | 0.5% | 0.6% | ||
| Q2 24 | 1.3% | 1.2% | ||
| Q1 24 | — | 1.0% |
现金转化率PLXTACT
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | 242.00× | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
TACT
暂无分部数据
